Omega-3 Supplementation to ADHD Medication in Children
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids
for deficient emotional self-regulation (DESR) as a supplement to Attention
Deficit/Hyperactivity Disorder (ADHD) treatment in children and adolescents with Attention
Deficit/Hyperactivity Disorder. Subjects will be between the ages of 6-17 and will currently
be on medication for their Attention Deficit/Hyperactivity Disorder but still experience DESR
traits.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Adderall Amphetamine Central Nervous System Stimulants Dextroamphetamine Methylphenidate